These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16313268)

  • 1. Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia.
    Nishio M; Endo T; Fujimoto K; Sato N; Sakai T; Obara M; Kumano K; Minauchi K; Koike T
    Eur J Haematol; 2005 Dec; 75(6):527-9. PubMed ID: 16313268
    [No Abstract]   [Full Text] [Related]  

  • 2. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
    Miles SA; McGratten M
    J Clin Oncol; 2005 Jan; 23(1):247-8. PubMed ID: 15625386
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus and monoclonal gammopathy in a post-nonmyeloablative stem cell transplant patient.
    Endo T; Nakao S; Koizumi K; Nishio M; Fujimoto K; Sakai T; Kumano K; Obara M; Koike T
    Ann Hematol; 2004 Feb; 83(2):114-6. PubMed ID: 14513283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma.
    Kamezaki K; Kikushige Y; Numata A; Miyamoto T; Takase K; Henzan H; Aoki K; Kato K; Nonami A; Kamimura T; Arima F; Takenaka K; Harada N; Fukuda T; Hayashi S; Ohno Y; Eto T; Harada M; Nagafuji K
    Bone Marrow Transplant; 2007 May; 39(9):523-7. PubMed ID: 17369863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy.
    Johnston A; Salles G; Espinouse D; Felman P; André P; Berger F; Coiffier B
    Clin Lymphoma Myeloma; 2008 Dec; 8(6):356-8. PubMed ID: 19064401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Primary diffuse large B-cell lymphoma of the bone marrow complicated with autoimmune hemolytic anemia and erythroid hypoplasia].
    Sumi M; Ichikawa N; Shimizu I; Yotsumoto M; Ueno M; Kobayashi H
    Rinsho Ketsueki; 2007 Jul; 48(7):571-5. PubMed ID: 17695307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal EBV-related post-transplant lymphoproliferative disorder (LPD) after matched related donor nonmyeloablative peripheral blood progenitor cell transplant.
    Zamkoff KW; Bergman S; Beaty MW; Buss DH; Pettenati MJ; Hurd DD
    Bone Marrow Transplant; 2003 Feb; 31(3):219-22. PubMed ID: 12621485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
    Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of primary pulmonary malignant lymphoma associated with autoimmune hemolytic anemia].
    Kubota Y
    Nihon Kokyuki Gakkai Zasshi; 2006 Jun; 44(6):453-7. PubMed ID: 16841717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma.
    Nishio M; Fujimoto K; Yamamoto S; Endo T; Sakai T; Obara M; Kumano K; Minauchi K; Yamaguchi K; Takeda Y; Sato N; Koizumi K; Mukai M; Koike T
    Eur J Haematol; 2006 Sep; 77(3):226-32. PubMed ID: 16923109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent advances and the treatment strategies of AIDS-related malignant lymphoma].
    Okada S
    Rinsho Ketsueki; 2008 Oct; 49(10):1490-8. PubMed ID: 18833933
    [No Abstract]   [Full Text] [Related]  

  • 12. Epstein-Barr virus associated diffuse large B-cell lymphoma complicated by autoimmune hemolytic anemia and pure red cell aplasia.
    Katayama H; Takeuchi M; Yoshino T; Munemasa M; Tada A; Soda R; Takahashi K
    Leuk Lymphoma; 2001 Jul; 42(3):539-42. PubMed ID: 11699422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
    Nishio M; Endo T; Fujimoto K; Yamamoto S; Obara M; Yamaguchi K; Takeda Y; Goto H; Kasahara I; Sato N; Koike T
    Eur J Haematol; 2009 Feb; 82(2):143-7. PubMed ID: 19018870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late-onset Epstein-Barr virus (EBV)-negative extranodal B-precursor lymphoblastic lymphoma of donor origin after hematopoietic stem cell transplantation (HSCT).
    Bredt M; Schönfeld G; Kleeberger W; König E; Kröning H; Kettner E; Al-Ali HK; Niederwieser D; Kreipe H
    Bone Marrow Transplant; 2003 Jun; 31(11):1071-2. PubMed ID: 12774065
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
    Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
    J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
    Coso D; Sebban C; Boulat O; Biron P; Rey J; Aurran T; Chabannon C; Xerri L; Chetaille B; Esterni B; Ivanov V; Stoppa AM; Schiano de Collela JM; Gastaut JA; Maraninchi D; Bouabdallah R
    Bone Marrow Transplant; 2006 Aug; 38(3):217-22. PubMed ID: 16770316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A long-lasting third complete remission after second autologous transplant followed by maintenance treatment with rituximab in a patient with diffuse large cell non-Hodgkin's lymphoma.
    Ataergin S; Arpaci F; Beyzadeoglu M; Safali M; Ozet A
    Am J Hematol; 2006 Dec; 81(12):986-7. PubMed ID: 16886214
    [No Abstract]   [Full Text] [Related]  

  • 18. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
    Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
    Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burkitt's lymphoma-- what is new?
    Abinya ON
    East Afr Med J; 2008 May; 85(5):205-6. PubMed ID: 18814529
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.